Evidence map›Paper›PMID 37138122›Full record

ReviewCell biology and toxicology2023

Potential functions and therapeutic implications of glioma-resident mesenchymal stem cells.

Qing Zhang, Jialin Wang, Junwen Zhang, Fusheng Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Qing Zhang *Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Jialin Wang *Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Junwen ZhangBrain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Fusheng LiuBrain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. liufusheng@ccmu.edu.cn.
Beijing Radiation Center · CNBeijing Tian Tan Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are emerging crucial regulators in the tumor microenvironment (TME), which contributes to tumor progression and therapeutic resistance. MSCs are considered to be the stromal components of several tumors, their ultimate contribution to tumorigenesis and their potential to drive tumor stem cells, especially in the unique microenvironment of gliomas. Glioma-resident MSCs (GR-MSCs) are non-tumorigenic stromal cells. The phenotype of GR-MSCs is similar to that of prototype bone marrow-MSCs and GR-MSCs enhance the GSCs tumorigenicity via the IL-6/gp130/STAT3 pathway. The higher percentage of GR-MSCs in TME results in the poor prognosis of glioma patients and illuminate the tumor-promoting roles for GR-MSCs by secreting specific miRNA. Furthermore, the GR-MSC subpopulations associated with CD90 expression determine their different functions in glioma progression and CD90

Indexed as

GliomaMesenchymal Stem CellsMicroRNAsForkhead Transcription FactorsHumansInterleukin-6Signal TransductionTumor MicroenvironmentForkhead Transcription FactorsFOXS1 protein, humanInterleukin-6MicroRNAsGliomaGlioma-resident mesenchymal stem cellsMesenchymal stem cellsTumor microenvironmentTumor-promoting

Identifiers

PMID37138122
OpenAlexW4367840365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.